Jan 17 2020: GMV announced to the market that clinical trials...

Jan 17 2020: GMV announced to the market that clinical trials were complete for NMPA.
Yacov is quoted saying "the company will shortly lodge the required documentation to the regulator and we are confident that NMPA approve will be received towards the middle of the year."
This link is from a site with the word stock and head in its name, so it might not show up here.
In the same article, an analyst is skeptical, calling it "a bit spivvy."
https://unauthorised investment advice/health/biotech-gmv-finishes-trial-needed-to-enter-chinese-market-shares-rally/
(The data was never lodged. A few months later, GMV officially denied it would delist from ASX, and promptly delisted.)